STRO-1+ Cell Therapy for Asthma Inflammation and Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory conditions such as asthma and COPD are limited in effectiveness, particularly for patients who do not respond to standard corticosteroid and bronchodilator therapies, and there is a need for new therapies that can address inflammation, airway hyperresponsiveness, and lung remodeling.
Innovation Solution
Administration of STRO-1+ cell preparations, which include enriched populations of STRO-1+ cells and their progeny, or soluble factors derived therefrom, to reduce TH2-mediated allergic responses, eosinophil infiltration, and inflammation in the lungs, thereby addressing bronchial hyperresponsiveness and lung remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids and β2-agonists are used to treat asthma, then airway inflammation and bronchodilation are improved, but 5 to 10% of patients still have symptomatic condition
Solution Approach 1:
The patent introduces a novel therapeutic agent (small molecule compound) that acts as an intermediary by targeting a different mechanism (phosphodiesterase inhibition) compared to existing corticosteroids and β2-agonists. This compound serves as a mediator that enhances the effect of existing therapies or provides alternative treatment pathway for non-responders, thereby improving overall treatment reliability across diverse patient populations
2Reliability
If corticosteroids are used to treat COPD, then inflammation is reduced, but inflammatory cells and mediators are not sensitive to treatment
Solution Approach 1:
The patent employs parameter changes by introducing a small molecule compound with a different mechanism of action (phosphodiesterase inhibition) that alters the therapeutic parameters for treating COPD inflammation. This compound changes the biochemical parameters of inflammation control by inhibiting phosphodiesterase enzymes, thereby achieving anti-inflammatory effects in patients who are insensitive to corticosteroid treatment
3Reliability
If current asthma therapies are used, then reversible airway obstruction is treated, but airway remodeling causes permanent changes that are not prevented
Solution Approach 1:
The patent applies preliminary action by introducing a small molecule compound that can prevent airway remodeling before permanent structural changes occur. The compound acts prophylactically by inhibiting phosphodiesterase enzymes involved in the remodeling process, thereby preventing the development of permanent airway structural changes while maintaining symptom control
Data Source
AI summary
The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.